Author(s): Sonja Jose, B. R. Balakrishnan

Email(s): jvchrsty@yahoo.co.in

DOI: 10.52711/0974-360X.2021.00415   

Address: Sonja Jose1*, B. R. Balakrishnan2
1Research Scholar, Department of Pharmaceutical Analysis, Vinayaka Mission College of Pharmacy, Vinayaka Mission’s Research Foundation (Deemed to be University), Salem, Tamilnadu.
2Professor and Head, Department of Pharmacognosy, Vinayaka Mission College of Pharmacy, Vinayaka Mission’s Research Foundation (Deemed to be University), Salem, Tamilnadu.
*Corresponding Author

Published In:   Volume - 14,      Issue - 4,     Year - 2021


ABSTRACT:
Cervical cancer imposes a huge global burden. Cervical carcinoma is one of the most common and feared diseases of women, and in India, it accounts for 16 per cent of total cervical cancer cases occurring globally. The situation is more alarming in the rural areas where the majority of women are illiterate and ignorant about the hazards of cervical cancer. To date, various studies have been conducted on the risk factors associated with cervical cancer. Accumulated evidence has demonstrated the reasons by which HPV infection causes carcinogenesis. Two viral oncoproteins E6 and E7could play a key role in the HPV-infected cervical cancers. It has been documented that not all integrations necessarily depend on the E6 and E7 oncogenes expression. Currently, clinical treatment managements for cervical cancer typically include surgery, radiotherapy, and platinum-based chemotherapy. Treatment for early stage disease often is surgical therapy such as cervical conisation, total simple hysterectomy, or radical hysterectomy based on extent of spread of cervical cancer. In the recent years, a series of systemic treatments, for instance, the platinum-based chemotherapy and the recent FDA approved pembrolizumab, have applied for recurrent and advanced cervical cancer. Although screening and advanced therapeutic strategies have improved the survival rate of cervical cancer, some patients still die due to metastasis and drug resistance. Without a doubt, HPV vaccination could pre-vent the development of cervical cancer; however, many patients’ in underdeveloped countries cannot get HPV vaccination due to economic condition. The aim of this study was to investigate the incidence, mortality, and geographical distribution of cervical cancer and its risk factors in the world and study the molecular mechanisms of cervical cancer development and progression, to discover the novel molecular diagnostic methods and systemic management for cervical cancer. The findings of this study demonstrated that several factors including sexually transmitted infections, reproductive factors, hormonal influences, genetics and host factors are responsible for the incidence of cervical cancer. The results of this review study suggested that combination of biological, economic and health factors contributes to the incidence of cervical cancer. A large proportion cervical cancer can be prevented by prevention programs, lifestyle enhancement, smoking cessation, and timely and effective treatment of pre-cancerous lesions.


Cite this article:
Sonja Jose, B. R. Balakrishnan. Cervical Cancer Prevention and Treatment: An Overview. Research Journal of Pharmacy and Technology. 2021; 14(4):2353-9. doi: 10.52711/0974-360X.2021.00415

Cite(Electronic):
Sonja Jose, B. R. Balakrishnan. Cervical Cancer Prevention and Treatment: An Overview. Research Journal of Pharmacy and Technology. 2021; 14(4):2353-9. doi: 10.52711/0974-360X.2021.00415   Available on: https://rjptonline.org/AbstractView.aspx?PID=2021-14-4-91


REFERENCES:
1. Parkin DM, Bray F, Ferlay J and Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2): 74-108.
2. Ma X and Yu H. Global Burden of Cancer. Yale Journal of Biology and Medicine.2006; 79(3-4): 85-94.
3. World Health Organization. The global burden of disease: 2004 update. Geneva: World Health Organization; 2008.
4. Wright AA, Howitt BE, Myers AP, Dahlberg SE, Palescandolo E and Van Hummelen P, et al. Oncogenic Mutations in Cervical Cancer: Genomic Differences Between Adeno carcinomas and Squamous Cell Carcinomas of the Cervix. Cancer. 2013; 19(21): 3776-83.
5. Zhen S, Hu CM and Bian LH. Glutathione S-transferase polymorphism interactions with smoking status and HPV infection in cervical cancer risk: an evidence-based meta-analysis. PloS one. 2013; 8(12): 83497.
6. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet‐Tieulent J and Jemal A. Global cancer statistics, 2012. CA: a cancer. Journal for clinicians. 2015; 65(2): 87-108.
7. Faridi R, Zahra A, Khan K and Idrees M. Oncogenic potential of Human Papilloma virus (HPV) and its relation with cervical cancer. Virology Journal. 2011; 8(1): 1-8.
8. Khan S, Jaffer NN, Khan MN, Rai MA, Shafiq M and Ali A et al., Human papilloma virus subtype 16 is common in Pakistani women with cervical carcinoma. International Journal of infectious diseases. 2007;11(4): 313-317.
9. Mittra I, Mishra GA, Singh S, Aranke S, Notani P and Badwe R. et al., A cluster randomized, controlled trial of breast and cervix cancer screening in Mumbai, India: methodology and interim results after three rounds of screening. International Journal of Cancer. 2010; 126(4): 976–984.
10. Prasad V, Kumar H and Mailankody S. Ethics of clinical trials in low-resource settings: lessons from recent trials in cancer medicine. Journal of Global Oncology 2016: 2(1): 1–3.
11. Lizano M, Berumen J and Garcia-Carranca A. HPV-related carcinogenesis: Basic concepts, viral types and variants. Archives Medical Research. 2009; 40: 428-34.
12. Yugawa T and Kiyono T. Molecular mechanisms of cervical carcinogenesis by high-risk human papillomaviruses: novel functions of E6 and E7 oncoproteins. Reviews in Medical Virology. 2009:19: 97-113.
13. Martinez-Lagunas A, Madrid-Marina V and Gariglio P. Modulation of apoptosis by early human papilloma virus proteins in cervical cancer. Biochim Biophys Acta. 2010; 1805: 6-16.
14. Schiffman M, Rodriguez A, Chen Z, Wacholder S, Herrero R and Hildesheim A, et al. A population-based prospective study of carcinogenic human papilloma virus variant lineages, viral persistence and cervical neoplasia. Cancer Research 2010:70; 3159-69.
15. Clifford GM, Smith JS, Plummer M, Muñoz N and Franceschi S. Human papilloma virus types in invasive cervical cancer worldwide: a meta-analysis. British Journal of Cancer. 2003; 88(1): 63–73.
16. Li N, Franceschi S, Howell-Jones R, Snijders PJF and Clifford GM. Human papilloma virus type distribution in 30,848 invasive cervical cancers world wide: Variation by geographical region, histological type and year of publication. International Journal of Cancer. 2011;128(4):927–35.
17. WHO. Human papillomavirus laboratory manual [Internet]. Geneva, Switzerland; 2010.
18. Centers for Disease Control and Prevention (CDC). HPV Vaccine Information for Clinicians - Fact Sheet [Internet]. 2012 [cited 2014 Dec 17.
19. For the HPV PATRICIA Study Group, Castellsagué X, Paavonen J, Jaisamrarn U, Wheeler CM, Skinner and SR, et al. Risk of first cervical HPV infection and precancerous lesions after onset of sexual activity: analysis of women in the control arm of the randomized, controlled PATRICIA trial. BMC Infect Dis [Internet]. 2014 [cited 2014 Dec 16];14(1). 
20. Collins S, Mazloomzadeh S, Winter H, Blomfield P, Bailey A and Young LS, et al. High incidence of cervical human papillomavirus infection in women during their first sexual relationship. BJOG International Journal of Gynaecology and obstetrics 2002;109(1): 96–8.
21. Kjaer SK, Chackerian B, van den Brule AJ, Svare EI, Paull G and Walbomers JM, et al. High-risk human papillomavirus is sexually transmitted: evidence from a follow-up study of virgins starting sexual activity (intercourse). Oncology. 2001;10(2):101–6.
22. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM and Leodolter S, et al. Quadrivalent Vaccine against Human Papilloma virus to Prevent Anogenital Diseases. New England Journal of Medicine: Research and Reviews. 2007; 356 (19):1928–43.
23. The Future II Study Group. Quadrivalent Vaccine against Human Papilloma virus to Prevent High-Grade Cervical Lesions. New England Journal of Medicine: Research and Reviews 2007;356 (19): 1915–27.
24. World Health Organization (WHO). Human papillomavirus vaccines: position paper, October 2014 [Internet]. 2014. 
25. Castle P, Schiffman M, Wheeler C and Solomon D. Evidence for frequent regression of cervical intra epithelial neoplasia—grade 2.Obstetrics and Gynecology 2009; 113:18-25.
26. Hildesheim A, Schiffman M, Gravitt P, Glass A, Greer C and Zhang T, et al. Persistence of type-specific human papilloma virus infection among cytologically normal women. Journal of Infected Disease. 1994; 169:235-40.
27. Thomas M, Narayan N, Pim D, Tomaic V, Massimi P and Ngasaka K, et al. Human papilloma viruses, cervical cancer and cell polarity. Oncogene 2008; 27:7018-30.
28. Dillner J, Meijer CJ, von Krogh G and Horenblas. Epidemiology of human papilloma virus infection. Scandinavian Journal of Urology Nephrology, 2000; 205,194-200.
29. Bonnez W and Reichman R. Papillomaviruses. In: Mandell G, Bennett J and Dolin R (eds) Mandell, Douglas, and Bennett’s principles and practice of infectious diseases.7th ed. Philadelphia, PA: Churchill Livingstone, 2010, pp.194–195.
30. Forman D, de Martel C and Lacey C, et al. Global burden of human papilloma virus and related diseases. Vaccine 2012; 20: F12–F23.
31. Dai M, Bao Y and Li N, et al. Human papilloma virus infection in Shanxi Province, People’s Republic of China: A population based study. British Journal of Cancer 2006; 95: 96–101.
32. Liu S, Chan K and Leung R, et al. Prevalence and risk factors of Human Papilloma virus (HPV) infection in southern Chinese women – a population-based study. PLoS ONE2011; 6: e19244.
33. Liu S, Yang Y and Yang H. Cervical cancer risk factor in Wudu, Gansu Province. Journal of Modern Oncology 2013; 21: 2793–2795.
34. Jiang B. Analysis of risk factors related to cervical cancer and precancerous lesions. Chinese Foreign Medical Research 2013; 11:30–31.
35. Donta B, Begum S, Nair S, Naik DD, Mali BN and Bandiwadekar A. Awareness of Cervical Cancer among Couples in a Slum area of Mumbai. Asian Pacific Journal of Cancer Prevention. 2012;13(10):4901-03.
36. Asthana S and Labani S. Factors associated with attitudes of rural women towards Cervical cancer screening, Noida, UP. Indian Journal of Community Medicine. 2013;38(4): 246-48.
37. Shah V, Vyas S, Singh A and Shrivastava M. Awareness and Knowledge of Cervical Cancer & its Prevention among the Nursing Staff of a Tertiary Health institute in Ahmedabad, Gujarat. E cancer medical science. 2012;6:270.
38. Marquina G, Manzano A and Casado A. Targeted Agents in Cervical Cancer: Beyond Bevacizumab. Current Oncology Report. 2018 Apr 2;20(5):40.
39. Hopkins TG and Wood N. Female human papilloma virus (HPV) vaccination: Global uptake and the impact of attitudes. Vaccine. 2013; 31(13):1673–9.
40. Levin A, Wang SA, Levin C, Tsu V and Hutubessy R. Costs of Introducing and Delivering HPV Vaccines in Low and Lower Middle Income Countries: Inputs for GAVI Policy on Introduction Grant Support to Countries. PLoS ONE. 2014;9(6):e101114. Metcalfe JZ, editor.
41. Oche MO, Kaoje AU and Gana G et al., Cancer of the cervix and cervical screening: Current knowledge, attitude and practices of female health workers in Sokoto, Nigeria. International Journal of Medicine and Medical Sciences. 2013; 5(4): 184–190.
42. Nwobodo EI and Malami SA. Knowledge and practice of cervical screening among female health workers in Sokoto, North Western Nigeria. Nigerian Postgraduate Medical Journal. 2005; 12(4): 255–257.

Recomonded Articles:

Author(s): A. Ashwatha Pratha, R. V. Geetha

DOI: 10.5958/0974-360X.2017.00240.2         Access: Open Access Read More

Author(s): C. Jegatha, V. Hemavathy, KR. Vasanthakohila

DOI: 10.5958/0974-360X.2015.00055.4         Access: Open Access Read More

Author(s): Raghotham S., Balamuralidhara V., Kamireddy Karuna

DOI: 10.5958/0974-360X.2019.00780.7         Access: Open Access Read More

Author(s): D Saha, D Mridha, S Mondal, M Jana, S Kayal

DOI: Not Available         Access: Open Access Read More

Author(s): Sathishkumar Venkatachalam, Lokeshkumar Boobathi, Maruthaiveeran Periyasamy Balasubramanian

DOI: Not Available         Access: Open Access Read More

Author(s): B. Reshmi, Gowri Sethu

DOI: 10.5958/0974-360X.2015.00214.0         Access: Open Access Read More

Author(s): Vysakh Visweswaran, Ameya Binoy, Anjana Sreenivas, B Abhinand, Meenu Vijayan

DOI: 10.5958/0974-360X.2017.00569.8         Access: Open Access Read More

Author(s): Sandip Zine, Shweta A. Patankar, Sushmita S. Raopati

DOI: 10.5958/0974-360X.2018.00588.7         Access: Open Access Read More

Author(s): Ketaki Shinde1, Usha Rani, Naveen Kumar. P

DOI: 10.5958/0974-360X.2018.00327.X         Access: Open Access Read More

Author(s): Rohitas Deshmukh, Sujata Kumari, Ranjit K. Harwansh

DOI: 10.5958/0974-360X.2020.00180.8         Access: Open Access Read More

Research Journal of Pharmacy and Technology (RJPT) is an international, peer-reviewed, multidisciplinary journal.... Read more >>>

RNI: CHHENG00387/33/1/2008-TC                     
DOI: 10.5958/0974-360X 

0.38
2018CiteScore
 
56th percentile
Powered by  Scopus


SCImago Journal & Country Rank


Recent Articles




Tags